In upregulated miRNAs in the serum, hsa-miR-627-5p can restrain pulmonary artery smooth muscle cell dysfunction by targeting MAP2K4 and PI3K/AKT signaling (71) and chronic lung disease, the most common complication in preterm infants (72). The gene discussed is MAP2K4; the disease is chronic lung disease.